Thank continue and you, with joining brief portfolio everyone, be record to to management half business non-opioid the thank in discussion the us. to performance. remarks you turning revenue drive cover recent continue proud our of Susan. team for pain of Good and year. morning, its prepared posted across highlights for throughout to today's progress I We'll questions. We quarter second innovation the begin first with before and your notable our
surgery allowed year quarter with deliver sites and for our most data sales I positive shortages, you underscoring outpace on ongoing with making combined market utilization surgery us exceeding ambulatory positive consecutive adjusted EBITDA XXst all million, market care. quarter marking certain headwinds, ever Relations key the were decreased the website. section our elective adjusted COVID recovery services invite the quarter, in our expanded sales of including impact of to our inflation intrusions, for across recent $XXX elective Flexion of centers operating last review in $XX.X it success EXPAREL and at hours labor EXPAREL rationale the with a the target million, the of to to IQVIA EBITDA. continues acquisition also Investor procedures, the product. our significantly of Strong second of the for highest million, ZILRETTA Second $XX was integration. contributor quarter Despite reduced sales hospital discipline
We business of this that market unequivocally and consistently are ability our variety can conditions. a say manage I our proud delivered. unpredictable record Pacira of to has across
our to invest improve growth, continue our to addition gross further fully we to Diego, our now initiatives suite XXX-liter in key margins, in revenue continued including installed. In which is San EXPAREL
expect allow We to and will to for improve and significant further growth submit provides new line margins. application that approval in are of FDA currently the XXXX. us This support top commissioning our facility this expansion equipment scale EXPAREL
line successful contract and to ZILRETTA aims a iovera° San and Diego our and manufacturer. quality that improve yield our facility the activities new Fremont Our transition from of to
EXPAREL-based our overview accelerated remains line Turning enabling continue drive and long-acting EXPAREL paradigm to now changes one times our recovery to of nerve focus driver franchise. an are as patient analgesia -- our top growth care. same-day blocks field and number Regional which in surgeries,
or beneficiaries. settings. CMS ensure which access our environments medical the reimbursement current and hospital The would on outpatient data In surgery comments for to parallel initiatives, ASC the outpatient with CMS EXPAREL EXPAREL Our antiquated utilizing centers for for we also surgeon are in for anesthesia Act, improvements proposed legislative continue patient for reduced of environment, action, blocks is seeking qualify customers to cumbersome outpatient they CXXXX. see recently to for separate allow all catheters. to rule NOPAIN replace satisfaction under EXPAREL-based system non-opioid opportunities equal reimbursement to economics of policy code in Medicare and Improved clear advantages issued also such pumps outpatient -- the whether prospective reimbursement. continuing the as payment XXXX ambulatory following agency and and as to care continued expand
Tampa in alone, the to inbound center transfer Erector and Our continues have from of we state-of-the-art In blocks accelerate sites requests real-time received migration and best most on pectoralis requesting teams select and plane facilitate transverse care. the outpatient spinae and with institutions XXXX highly abdominis to knowledge practice for anesthesia training their surgery XXX surgical requested. innovation PITT training blocks
training PITT medical training management education as our remain Our programs enabling are for well society approaches in-person regional us who eager engage with for pain as to directly at and meetings clinicians around in EXPAREL for increased to ZILRETTA nerve EXPAREL. base. customer also and growing provide educational These strong iovera°. is also drug-free with visibility expand and interest This our a blocks iovera° programs
facility we We expect later positive training in of innovation field have our Houston and Houston, clinicians, among are for on nerve on second especially procedures. real EXPAREL build-out to and impact remains an expanding iovera° will on the which and block track open expertise making progress year. blocks this equally
patents to with in new we recently This listed and Book surgery largest expect United robust that one centers. ambulatory finalized patents to the We new soon. notice very in of Orange patent extend with faith-based States. to and hospitals approximately our XX continue national system FDA more we allowance advance Xth health private Importantly, strategy XXX X states the agreement that in of have health recently XX than operates issue a around with the received our care now for to EXPAREL property patent intellectual January XX, We fortify a a XXXX. protection systems
our will across care EXPAREL-based education teams. also work within institutionalize lines agreement localized this an provides by opioid-sparing system. opportunity provided sites This extensive iovera° protocols through service with their field-based expand together utilization to clinical training to of We
driver Cleveland Investigators prior a showing dental maxillofacial will affiliated few continuous St. featured Scoliosis in EXPAREL authored meaningful continue dentists is The mount message in IQVIA many a up exposures. Texas, multiple for The more North year Orthopedic centers and a EXPAREL-based Research sites also hospital Doctors continues Hospital approach. into and infiltration the and EXPAREL key who in XX up reliably our XX% ambulated and of dental shift in sooner. year-over-year advance Society Meeting XX-hour surgery. C-section, dental Children XX women's to place in fusion platform and recent require ropivacaine. the Exchange, safely breast with over Rady procedures group than in for protocols we in patient Scottish will utilization the a through Safety see strong EXPAREL-based study January, XX strong Clinic in continues purchasing the organization of these surgery children Diego. data We infusion of care. enabling with augmentation network education expanded X.X with serving highlighted awareness with partnership driving efficacy with utilization will opioid our accounts, The are support group oral medical to in the drilling growth their Separately, to which awareness a annual as sites is of training working in procedures to large using the times This of generate a Hospitals, is space, around be Dallas, nation's most series, hours utilization the organization practices from continues practice San EXPAREL new EXPAREL treating will children oncology of and an introduce be by and where we of over In pediatrics, to mission-critical continue X,XXX study Macintosh optimizing of to gynecologic XXX experience multiple Together, growth opioid Louis around May be compared launching their at a care. support from less as make Rite Journal Orthopedic XX-hour our from McLeod to continue In to America the and the Shriners annualized opioid-sparing success published at in purchasing consumed key regional a issue EXPAREL hours XX%. approximately markets. progress. at spinal taking recovery to also Pediatric a to features data This orthopedic include are initiatives partnership such procedures thought new organizations pediatric of September. largest generated. from in health, after surgeries was the monthly posterior one to to best leaders education and study XXX undergoing epidural down with to shift Pediatric children that states. EXPAREL allow significant significantly to there access group in leading
health our clear reduced and key several but value across relevant Regarding slow and steady EXPAREL hospitals and the important launch, trust with backlog we have U.K., throughput. in service seeing progress European adopted length increased launches the are is stay national countries. surgical enabling proposition of our the in surgical In several EXPAREL
major from influence has repeat retention, feedback and strong customer several been New had orders we've with positive hospitals.
an continue we for team, strengthen Europe confident important our opportunity over forward, EXPAREL Pacira. time, and Moving market that to represents
pipeline. Moving evaluating to enrolled. extremity nerve the Both EXPAREL are lower studies our III of blocks now Phase fully
for stellate believe to from for $XXX EXPAREL market prevent in second X early expect studies these nerve million. cardiac world the line fibrillation treating and for September support extremity least is the surgery. expert lower report Shivkumar, approximately from study Arrhythmia after a to block also We of with a postoperative in NDA million dysrhythmias underway market, and upper renowned registration an refractory top the filing early Director year of If team. use to Planning supplemental study successful, first of We data study weeks the and X is approximately procedures atrial will cardiac next the with open at the mechanisms ventricular label later. Dr. addressable results is as roughly year. opportunity Cardiac of a collaborating as block follow heart extremity a with Center multicenter UCLA significant dysrhythmias as ganglion
with strategy We study ganglion are finalize in with significant who dysrhythmias. to After and days, the unmet help anesthesia need leaders our stellate registration block blocks EXPAREL an proceed utilizing convene committee a this of several A this ventricular to a in align fall for lasts for key address working include opinion expanding and ganglion which FDA a design. meeting we regulatory to patients stellate regional trial. will will will EXPAREL, label indication, atrial steering with
the remain integration with rationale strong and its the be the osteoarthritis underscores studies the will acquisition. an remains we expansion our second the and osteoarthritis sales of designs revenue our knee. Currently, early by for extended-release and we earnings quarter are EXPAREL, important for for pain trajectory, diabetes. in Beyond as success contributor and growth were performance the ZILRETTA successful strong augmented FDA-approved in it at shoulder X stage ZILRETTA only confident corticosteroid type label finalizing which
we end, is steroid with intra-articular immediate that prediabetic and in have in release process improves providing the a glycemic in and an Flexion and spikes. with To triamcinolone community reduced the a that significantly study osteoarthritis and tremendous acetonide. diabetes opportunity there data to efficacy comparing are diabetes safer We believe reanalyzed is the initiating of diabetic ZILRETTA
to osteoarthritis, as we also acetonide superiority We only are shoulders. for opportunity surgery. and shoulder for to ZILRETTA a preparing commercial These release make patients incremental an first study for shoulder reimbursement could and which the use in of also triamcinolone enhance ZILRETTA studies approved media for in ZILRETTA steroid demonstrate versus diabetic provide
through of to or the very efficiencies. rollout the improved base design presence Generation tournaments in has Golf X market launched the iovera°, appreciating the Moving recently practitioners positive partnership on the increased Professional we broad our more new major PGA our feedback with -- Association customer our device Tour underway, dedicated Tour the been user-friendly an iovera° device, Americas of had QX. X a is to Senior iovera° at novel with and cryotherapy and Corporation handheld and platform which We the
Charles guests PGA logo the which Cup the PGA we where with spectators November, local in make providers Champions to the and treatments. Our allow be and Tour next an cool Schwab event will zone a iovera° Tour appointments Champions iovera° will iovera° Championship for wearing have will player tent, of
and management that reduce use with benefits focus also sports options retired we include can Our the awareness educating options. of and opioids will or non-opioid need of management. up initiatives for even sports availability pain pain of non-opioid players, for organizations NFL Alumni the importance increase about the on Together, teaming the eliminate staff Association to
to Turning the iovera° pipeline.
Winston, data. The evaluate these now have collaborating on teams treatment in of and our President research findings In for Association highly for Paul our clinical with are a strategies As Medicine we medical for submitted design the FDA we iovera° registration in Physical may as patients. spasticity. parallel, are encouraging, Winston's publication studies Rehabilitation Dr. recall, and has been observational spasticity study Canadian a of post-stroke and the to preliminary of iovera° to conducting of Dr. you
iovera°. the meeting treatment will then with for is ganglion of also initiating Dr. with a as this block registration both Shivkumar EXPAREL for a various disease acute scheduled EXPAREL FDA to study a to and address in parallel stellate year spasticity proceed iovera° have with We utilizing with and the trial cardiac the iovera° dysrhythmia. address study. wide the later effectively We approach In and patients. a potential cryo have range cardiac of persistent long-lasting believe technology the our
to earlier-stage now our opportunities continue progress. Moving to we pipeline where make
We expect of year liposome, subarachnoid multi-vesicular initiate Phase year. study II the to second for Phase and to I our move our half this next analgesia bupivacaine later of
ambitious or innovative in the pain all ability strong pathway pain formulations ability high-dose for goals to along proprietary limited leadership confidence significant In bupivacaine made we addition, over position we turn than building our progress achieve financial corporate we more commercial our and significant management and X more. while Charlie? neuro delivering and us plans our of in pain I'll the competition, options ever Charlie the to days our to confident for delivering clinical multi-vesicular that, shareholder closing, our converging his value. are earnings non-opioid to highlights. liposome programs patients to longer-acting for are our even solutions opioid-sparing growth. cement need revenue the for give and for lower With for With defining patient call a with for greater dexamethasone date, are back inflammation along future in In have of
